Clinical trial
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
Name
CIDP07
Description
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
Trial arms
Treatment
Rozanolixizumab
Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
Size
-1
Eligibility criteria
Inclusion Criteria:
* Patient who has taken part in the CIDP04 (NCT04051944) study
* Patient who derives continued benefit from treatment
* All required safety information has been reported as per local laws/regulations, reported to Bionical, as appropriate, and documented in the patient's medical records
* Patient is not pregnant
Exclusion Criteria:
Protocol
{'studyType': 'EXPANDED_ACCESS', 'nPtrsToThisExpAccNctId': 2, 'expandedAccessTypes': {'individual': True}}
Updated at
2024-01-25
1 organization
1 product
1 indication
Organization
UCB BiopharmaProduct
Rozanolixizumab